Current status of diabetes in India and need for novel therapeutic agents

Journal of Association of Physicians of India

Volumn 58, Issue SPEC. ISSUE, 2010, Pages 7-9

  Ramachandran, A ^a   Das, A K ^b   Joshi, S R ^c   Yajnik, C S ^d   Shah, S ^e   Kumar, K M Prasanna ^f  

^a Dr A Ramachandran's Diabetes Hospitals   (India)

^b JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c Leelavati Hospital   (India)

^d KEM HOSPITAL   (India)

^e Raheja Hospital   (India)

^f M S RAMAIAH MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955812115     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. IDF Diabetes Atlas, 4th edition. International Diabetes Federation, 2009.
2. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40.
3. Ramachandran A, Wan Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375:408-18.
4. Yang W, Lu J, Weng J, et al. Prevalence of dibaetes among men and women in China. N Engl J Med 2010;362:1090-101.
5. Mohan V, Pradeepa R. Epidemiology of diabetes in different regions of India. Health Administrator 2009;22:1-18.
6. Ramachandran A, Snehalatha C, Kapur A, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001;44:1094-101.
7. Ramachandran A, Snehalatha C. Current scenario of diabetes in India. J Diabetes 2009;18-28.
8. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
10. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 2004;27(Suppl 1):S91-S93.
11. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Costeffectiveness of the interventions in the primary prevention of diabetes among Asian Indians: Within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007;30:2548- 52.
12. Zimmet P. The burden of type 2 diabetes: Are we doing enough? Diabetes Metab 2003;29:6S9-6S18.
13. Raheja BS, Kapur A, Bhoraskar A, et al. DiabCare Asia-India Study: Diabetes care in India-Current status. J Assoc Physicians India 2001;49:717-22.
14. Nagpal J, Bhartia A. Quality of diabetes care in the middle- and high-income group populace: The Delhi Diabetes Community (DEDICOM) survey. Diabetes Care 2006;29:2341-8.
15. Ramachandran A, Mary S, Sathish CK et al. Population based study of quality of diabetes care in southern India. JAPI 2008;56:513-16.
16. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: The Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci 2005;46:2328-33.
17. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004;36:747-54.
18. Alder AI, Shaw EJ, Stokes T, Ruiz F. Newer agents for blood glucose control in type 2 diabetes: Summary of NICE guidance. BMJ 2009;338.
19. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the longacting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42.
20. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-21.